DPP4 and fasciitis: The most common adverse event of SGLT2i as a group, compared with placebo groups, is mycotic infections, particularly among females.55 A metanalysis found that the risk of mycotic genital infections is lower when SGLT2i is combined with dipeptidyl peptidase-4 (DPP-4) inhibitors than when they are used as a monotherapy or as an adjunct to metformin.56 Necrotizing fasciitis of the perineum, called Fournier’s gangrene, is a significant adverse event, although post-marketing case reviews show a lower incidence than initially reported.57